Optimal management of cancer cachexia-anorexia syndrome

According to a recent consensus, cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the majority of cancer patients before deat...

ver descrição completa

Detalhes bibliográficos
Autores: Huguet, José María, Olivan Riera, Mireia, Busquets Rius, Sílvia, López-Soriano, Francisco J.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2010
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/169408
Acesso em linha:https://hdl.handle.net/2445/169408
Access Level:acceso abierto
Palavra-chave:Anorèxia nerviosa
Càncer
Medicaments
Anorexia nervosa
Cancer
Drugs
id ES_70f20ca3a2d2b5b6fd6899b72be59e6f
oai_identifier_str oai:recercat.cat:2445/169408
network_acronym_str ES
network_name_str España
repository_id_str
spelling Optimal management of cancer cachexia-anorexia syndromeHuguet, José MaríaOlivan Riera, MireiaBusquets Rius, SílviaLópez-Soriano, Francisco J.Anorèxia nerviosaCàncerMedicamentsAnorexia nervosaCancerDrugsAccording to a recent consensus, cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the majority of cancer patients before death and it is responsible for the deaths of 22% of cancer patients. Although bodyweight is the most important endpoint of any cachexia treatment, body composition, physical performance and quality of life should be monitored. From the results presented here, one can speculate that a single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful. The objectives of any therapeutic combination are two-fold: an anticatabolic aim directed towards both fat and muscle catabolism and an anabolic objective leading to the synthesis of macromolecules such as contractile proteins.Dove Medical Press2020202020102020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion12 p.application/pdfhttps://hdl.handle.net/2445/169408Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.2147/cmar.s7101Cancer Management and Research, 2010, vol. 2, p. 27-38https://doi.org/10.2147/cmar.s7101cc-by-nc (c) Huguet, Josep Ma. et al., 2010http://creativecommons.org/licenses/by-nc/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/1694082026-05-29T05:05:01Z
dc.title.none.fl_str_mv Optimal management of cancer cachexia-anorexia syndrome
title Optimal management of cancer cachexia-anorexia syndrome
spellingShingle Optimal management of cancer cachexia-anorexia syndrome
Huguet, José María
Anorèxia nerviosa
Càncer
Medicaments
Anorexia nervosa
Cancer
Drugs
title_short Optimal management of cancer cachexia-anorexia syndrome
title_full Optimal management of cancer cachexia-anorexia syndrome
title_fullStr Optimal management of cancer cachexia-anorexia syndrome
title_full_unstemmed Optimal management of cancer cachexia-anorexia syndrome
title_sort Optimal management of cancer cachexia-anorexia syndrome
dc.creator.none.fl_str_mv Huguet, José María
Olivan Riera, Mireia
Busquets Rius, Sílvia
López-Soriano, Francisco J.
author Huguet, José María
author_facet Huguet, José María
Olivan Riera, Mireia
Busquets Rius, Sílvia
López-Soriano, Francisco J.
author_role author
author2 Olivan Riera, Mireia
Busquets Rius, Sílvia
López-Soriano, Francisco J.
author2_role author
author
author
dc.subject.none.fl_str_mv Anorèxia nerviosa
Càncer
Medicaments
Anorexia nervosa
Cancer
Drugs
topic Anorèxia nerviosa
Càncer
Medicaments
Anorexia nervosa
Cancer
Drugs
description According to a recent consensus, cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the majority of cancer patients before death and it is responsible for the deaths of 22% of cancer patients. Although bodyweight is the most important endpoint of any cachexia treatment, body composition, physical performance and quality of life should be monitored. From the results presented here, one can speculate that a single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful. The objectives of any therapeutic combination are two-fold: an anticatabolic aim directed towards both fat and muscle catabolism and an anabolic objective leading to the synthesis of macromolecules such as contractile proteins.
publishDate 2010
dc.date.none.fl_str_mv 2010
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/169408
url https://hdl.handle.net/2445/169408
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.2147/cmar.s7101
Cancer Management and Research, 2010, vol. 2, p. 27-38
https://doi.org/10.2147/cmar.s7101
dc.rights.none.fl_str_mv cc-by-nc (c) Huguet, Josep Ma. et al., 2010
http://creativecommons.org/licenses/by-nc/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc (c) Huguet, Josep Ma. et al., 2010
http://creativecommons.org/licenses/by-nc/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 12 p.
application/pdf
dc.publisher.none.fl_str_mv Dove Medical Press
publisher.none.fl_str_mv Dove Medical Press
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410617257885696
score 15,811543

Registos relacionados